Go Deep
BioStem Technologies, Inc.
BioStem Technologies, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 25,303 | 2.3 | 1.38 | 0.04 | 193.22 |
| Oct 2026 | 25,257 | 2.4 | 1.41 | 0.04 | 197.95 |
| Oct 2026 | 25,771 | 1.8 | 1.04 | 0.04 | 146.02 |
| Oct 2026 | 25,677 | 1.9 | 1.11 | 0.04 | 155.50 |
| Oct 2026 | 25,640 | 1.9 | 1.14 | 0.04 | 158.90 |
| Oct 2026 | 25,659 | 1.9 | 1.12 | 0.04 | 156.69 |
BioStem Technologies, Inc. Quarterly Results
| Line Item | Jun 2026 | Sep 2025 | Jun 2025 |
|---|---|---|---|
| Revenue | 7,899,249.0 | 10,473,402.0 | 10,963,174.0 |
| Net Profit | -8,971,360.0 | 761,052.0 | 10,613.0 |
| EPS | -0.5 | 0.1 | 0.0 |
BioStem Technologies, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Revenue | 301,827,302.0 | 16,685,405.0 | 6,875,202.0 | 4,340,839.0 |
| Net Profit | 31,884,321.0 | -8,482,984.0 | -7,192,949.0 | -1,445,383.0 |
| EPS | 1.9 | -0.6 | -0.6 | -0.1 |
BioStem Technologies, Inc. Balance Sheet
| Line Item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Total Assets | 140,375,727.0 | 14,560,291.0 | 3,466,433.0 | 2,671,515.0 |
| Total Liabilities | 99,500,195.0 | 15,904,667.0 | 7,416,385.0 | 8,465,622.0 |
| Total Equity | 40,875,532.0 | -1,344,376.0 | -4,076,396.0 | -5,959,398.0 |
Owes vs Owns
BioStem Technologies, Inc. owed $0.43 for every $1 it owned in Jun 2026, down from $3.17 in Dec 2021.
| Period | Jun 2026 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
| Owes vs Owns | 0.43× | 0.71× | 1.09× | 2.14× | 3.17× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
BioStem Technologies, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2024
Cash & short-term investments 16.3%Receivables 75.7%Inventory 1.3%Fixed assets (tangible) 1.4%Other assets 5.0%
How it's funded — Dec 2024
Short-term debt 2.8%Payables 3.8%Other liabilities 64.2%Shareholders' equity 29.1%
| Line Item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 22.8 | 0.2 | 0.8 | 0.3 |
| Receivables | 106.2 | 11.4 | 0.0 | 0.3 |
| Inventory | 1.8 | 0.7 | 0.4 | 0.3 |
| Fixed assets (tangible) | 2.0 | 1.4 | 1.4 | 1.3 |
| Intangible assets | 0.5 | 0.6 | 0.6 | 0.5 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 7.1 | 0.3 | 0.3 | 0.0 |
| Liabilities & equity | ||||
| Short-term debt | 4.0 | 4.4 | 4.0 | 3.0 |
| Long-term debt | 0.1 | 0.3 | 1.0 | 1.8 |
| Payables | 5.3 | 0.9 | 0.6 | 0.6 |
| Other liabilities | 90.1 | 10.3 | 1.8 | 3.0 |
| Shareholders' equity | 40.9 | -1.3 | -3.9 | -5.8 |
| Net tangible assets | 40.4 | -1.9 | -4.7 | -6.4 |
BioStem Technologies, Inc. Cash Flow
| Line Item | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|
| Operating Activities | 24,476,653.0 | -3,498,960.0 | 303,575.0 | -109,439.0 |
| Investing Activities | -1,676,569.0 | -210,330.0 | -469,484.0 | -7,848.0 |
| Financing Activities | -206,784.0 | 3,176,560.0 | 597,712.0 | 357,421.0 |